The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women

Aim: The purpose of our study is to compare the changes in bone mineral density (BMD) in postmenopausal women who had uninterrupted risedronate sodium and strontium ranelate treatment for 3 years. Material and Methods: Eighty-five postmenopausal women with primer osteoporosis who had uninterrupted...

Full description

Bibliographic Details
Main Authors: Figen Yılmaz, Beril Doğu, Hülya Şirzai, Banu Kuran
Format: Article
Language:English
Published: Galenos Yayinevi 2012-08-01
Series:Türk Osteoporoz Dergisi
Subjects:
Online Access:http://www.turkosteoporozdergisi.org/article_4303/The-Comparison-Of-The-Effect-Of-Risedronate-And-Strontium-Ranelate-On-Bone-Mineral-Density-In-Postmenopausal-Women
_version_ 1797915780524802048
author Figen Yılmaz
Beril Doğu
Hülya Şirzai
Banu Kuran
author_facet Figen Yılmaz
Beril Doğu
Hülya Şirzai
Banu Kuran
author_sort Figen Yılmaz
collection DOAJ
description Aim: The purpose of our study is to compare the changes in bone mineral density (BMD) in postmenopausal women who had uninterrupted risedronate sodium and strontium ranelate treatment for 3 years. Material and Methods: Eighty-five postmenopausal women with primer osteoporosis who had uninterrupted risedronate sodium (A) (35 mg/week), strontium ranelate (P) (2 g/day) and calcium (1000 mg/day) - vitamin D (880 IU/day) supplementation for 3 years were included in our retrospective study. The demografic data and the yearly BMD measurements (lumbar spine, femur neck and femur total BMD and t scores) were recorded. Results: Group A had 34, and Group P had 51 patients. The mean age of the patients were 62.06±9.16 years and 60.30±7.68 years; and duration of menopause was 16.32±7.81 years and 16.78±8.34 years, respectively. There was statistically no significant difference between the groups regarding age, weight, body mass index, duration of menopause, menarche and menopause age, the lumbar spine, femur neck and total BMD and t scores at the beginning. At the end of uninterrupted 3 years of treatment, statistically significant increase was detected in lumbar spine and femur BMD measurements in Groups A and P (p<0.0001). Statistically significant increase was detected also in lumbar spine t scores in both groups. However, the femur t scores were found not to improve significantly in Group A, while in P, there was significant improvement. When the differences of improvement were compared, there was no difference between Group A and P regarding lumbar spine and femur BMD improvements. Conclusion: There was significant improvement in lumbar spine and femur BMD for Groups A and P at the end of 3 years of treatment for both medical agents, and improvement is similar for both agents. (Turkish Journal of Osteoporosis 2012;18: 58-62)
first_indexed 2024-04-10T12:47:06Z
format Article
id doaj.art-26397a1b0ca2406db37b65d1c99d9efc
institution Directory Open Access Journal
issn 2147-2653
language English
last_indexed 2024-04-10T12:47:06Z
publishDate 2012-08-01
publisher Galenos Yayinevi
record_format Article
series Türk Osteoporoz Dergisi
spelling doaj.art-26397a1b0ca2406db37b65d1c99d9efc2023-02-15T16:14:00ZengGalenos YayineviTürk Osteoporoz Dergisi2147-26532012-08-01182586210.4274/tod.54775The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal WomenFigen Yılmaz0Beril Doğu1Hülya Şirzai2Banu Kuran3Şişli Etfal Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İstanbul, TürkiyeŞişli Etfal Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İstanbul, TürkiyeŞişli Etfal Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İstanbul, TürkiyeŞişli Etfal Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İstanbul, TürkiyeAim: The purpose of our study is to compare the changes in bone mineral density (BMD) in postmenopausal women who had uninterrupted risedronate sodium and strontium ranelate treatment for 3 years. Material and Methods: Eighty-five postmenopausal women with primer osteoporosis who had uninterrupted risedronate sodium (A) (35 mg/week), strontium ranelate (P) (2 g/day) and calcium (1000 mg/day) - vitamin D (880 IU/day) supplementation for 3 years were included in our retrospective study. The demografic data and the yearly BMD measurements (lumbar spine, femur neck and femur total BMD and t scores) were recorded. Results: Group A had 34, and Group P had 51 patients. The mean age of the patients were 62.06±9.16 years and 60.30±7.68 years; and duration of menopause was 16.32±7.81 years and 16.78±8.34 years, respectively. There was statistically no significant difference between the groups regarding age, weight, body mass index, duration of menopause, menarche and menopause age, the lumbar spine, femur neck and total BMD and t scores at the beginning. At the end of uninterrupted 3 years of treatment, statistically significant increase was detected in lumbar spine and femur BMD measurements in Groups A and P (p<0.0001). Statistically significant increase was detected also in lumbar spine t scores in both groups. However, the femur t scores were found not to improve significantly in Group A, while in P, there was significant improvement. When the differences of improvement were compared, there was no difference between Group A and P regarding lumbar spine and femur BMD improvements. Conclusion: There was significant improvement in lumbar spine and femur BMD for Groups A and P at the end of 3 years of treatment for both medical agents, and improvement is similar for both agents. (Turkish Journal of Osteoporosis 2012;18: 58-62)http://www.turkosteoporozdergisi.org/article_4303/The-Comparison-Of-The-Effect-Of-Risedronate-And-Strontium-Ranelate-On-Bone-Mineral-Density-In-Postmenopausal-WomenOsteoporosistreatmentbone mineral densityrisedronate sodiumstrontium ranelate
spellingShingle Figen Yılmaz
Beril Doğu
Hülya Şirzai
Banu Kuran
The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
Türk Osteoporoz Dergisi
Osteoporosis
treatment
bone mineral density
risedronate sodium
strontium ranelate
title The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
title_full The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
title_fullStr The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
title_full_unstemmed The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
title_short The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
title_sort comparison of the effect of risedronate and strontium ranelate on bone mineral density in postmenopausal women
topic Osteoporosis
treatment
bone mineral density
risedronate sodium
strontium ranelate
url http://www.turkosteoporozdergisi.org/article_4303/The-Comparison-Of-The-Effect-Of-Risedronate-And-Strontium-Ranelate-On-Bone-Mineral-Density-In-Postmenopausal-Women
work_keys_str_mv AT figenyılmaz thecomparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT berildogu thecomparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT hulyasirzai thecomparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT banukuran thecomparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT figenyılmaz comparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT berildogu comparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT hulyasirzai comparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen
AT banukuran comparisonoftheeffectofrisedronateandstrontiumranelateonbonemineraldensityinpostmenopausalwomen